VistaGen Therapeutics (VTGN) AI Stock Analysis

• Market Cap: $68.11M
• Dividend Yield: N/A
• Average Volume (3M): 143.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: -33.00%
• EPS Growth: 54.91%
• Country: US
• Employees: 48
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.43
• Shares Outstanding: 28,862,085
• 10 Day Avg. Volume: 122,035
• 30 Day Avg. Volume: 143,058
• PEG Ratio: -0.02
• Price to Book (P/B): 2.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.50
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: 3.09
• Enterprise Value/Gross Profit: 20.72
• Enterprise Value/Ebitda: -0.07
• 1Y Price Target: $12.00
• Price Target Upside: 404.20% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

VistaGen Therapeutics faces significant financial difficulties, with substantial losses and negative cash flows, which are major risk factors. The technical analysis indicates a bearish trend, compounded by an unattractive valuation due to its negative P/E ratio. While the earnings call highlighted progress in clinical trials and a strong cash position, the increased R&D expenses and net loss are concerns. Overall, the stock remains speculative with significant challenges ahead.

Positive Factors

Clinical Trials

Positive results from the prior PALISADE-2 study increase confidence in ongoing Phase 3 trials for social anxiety disorder.

Drug Development

VistaGen introduced PH284, another neuroactive spray in its pipeline, for the treatment of cancer cachexia, and reported positive P2a results.

Financial Stability

VistaGen has $97.6M in cash, providing financial runway through FY26.

Negative Factors

Earnings

VistaGen reported F3Q25 results with a net loss of ($14.1M).

VistaGen Therapeutics Business Overview & Revenue Model

Company Description

VistaGen Therapeutics, Inc. (VTGN) is a clinical-stage biopharmaceutical company that focuses on developing innovative medicines for central nervous system (CNS) disorders. The company primarily works on creating therapies that address major depressive disorder, social anxiety disorder, and other CNS-related conditions. VistaGen's approach involves using its proprietary technologies to advance its pipeline of novel drug candidates aimed at improving the quality of life for individuals suffering from these disorders.

How the Company Makes Money

VistaGen Therapeutics makes money primarily through the development and commercialization of its drug candidates. The company seeks to generate revenue by bringing its CNS therapies to market, either independently or through strategic partnerships and collaborations with other pharmaceutical companies. These partnerships may involve licensing agreements, co-development deals, and milestone payments, as well as royalties from the sale of successfully approved and marketed drugs. Additionally, VistaGen may receive funding from grants and research collaborations that support its ongoing clinical trials and research initiatives.

VistaGen Therapeutics Financial Statement Overview

Summary

VistaGen Therapeutics faces significant financial challenges with negative growth, profitability, and cash flow metrics. The company operates with substantial losses and negative cash flows, relying on equity to maintain operations. Despite a strong equity base, it needs to address profitability and cash generation to ensure sustainability.

Income Statement

VistaGen Therapeutics has shown volatile revenue with a significant drop in the TTM period to $698,300 from $1,064,000 in the previous annual report, resulting in a negative revenue growth rate. The company incurs significant losses with a net profit margin of -6769% for TTM, indicating severe profitability issues. EBIT and EBITDA margins are deeply negative, highlighting operating inefficiencies.

Balance Sheet

The company has a relatively stable equity base with a positive equity ratio of 87.9% for TTM. However, the debt-to-equity ratio is low at 0.02, suggesting minimal leverage but also reflecting limited financial flexibility. Return on equity is negative due to consistent net losses.

Cash Flow

VistaGen Therapeutics shows a negative free cash flow, worsening by approximately 51.6% in the TTM compared to the previous period. The operating cash flow to net income ratio is negative, indicating poor cash conversion. The company relies heavily on financing activities to manage liquidity.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
698.30K	1.06M	-227.00K	1.11M	1.09M	0.00
	Gross Profit
537.30K	1.06M	-227.00K	1.11M	1.09M	0.00
	EBIT
-52.84M	-33.02M	-59.27M	-47.78M	-17.93M	-20.80M
	EBITDA
-52.38M	-32.45M	-58.74M	-47.05M	-17.44M	-20.65M
	Net Income Common Stockholders
-47.30M	-29.36M	-59.25M	-47.76M	-17.93M	-20.77M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
88.56M	119.17M	16.64M	68.14M	103.11M	1.36M
	Total Assets
92.31M	123.65M	21.09M	74.64M	108.28M	5.77M
	Total Debt
1.71M	2.12M	2.72M	3.04M	3.72M	4.09M
	Net Debt
-73.00M	-117.05M	-13.92M	-65.10M	-99.39M	2.74M
	Total Liabilities
11.19M	9.37M	9.01M	9.93M	16.30M	11.50M
	Stockholders Equity
81.12M	114.29M	12.08M	64.72M	91.98M	-5.73M
Cash Flow		Free Cash Flow
-39.26M	-25.87M	-49.93M	-45.46M	-12.35M	-15.76M
	Operating Cash Flow
-39.23M	-25.81M	-49.72M	-45.26M	-12.07M	-15.76M
	Investing Cash Flow
-13.70M	-61.00K	-740.30K	-200.40K	-275.40K	0.00
	Financing Cash Flow
1.09M	128.40M	-1.04M	10.48M	114.10M	4.01M

VistaGen Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.38
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTGN, the sentiment is Neutral. The current price of 2.38 is below the 20-day moving average (MA) of 2.41, above the 50-day MA of 2.31, and below the 200-day MA of 2.72, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 50.43 is Neutral, neither overbought nor oversold. The STOCH value of 42.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VTGN.

VistaGen Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.34B	3.36	-45.10%	3.39%	16.81%	-0.03%
SAVA	43 Neutral	$99.03M	―	-70.59%	―	―	81.00%
CLSD	40 Underperform	$61.89M	―	91.63%	―	-55.47%	24.92%
VTGN	39 Underperform	$68.11M	―	-46.28%	―	-33.00%	54.91%
VTVT	38 Underperform	$50.76M	―	-130.16%	―	―	65.54%
INZY	37 Underperform	$256.31M	―	-141.69%	―	―	-17.06%
JSPR	35 Underperform	$84.57M	―	-101.34%	―	―	21.40%

VistaGen Therapeutics Corporate Events

VistaGen Reports Q3 2025 Financial Results and Updates

On February 13, 2025, Vistagen reported its financial results for the fiscal year 2025 third quarter and provided a corporate update, highlighting advancements in its clinical-stage pipeline. Notably, the company is progressing with Phase 3 trials for fasedienol in the treatment of social anxiety disorder and announced positive results from a Phase 2A trial of PH284 in cancer cachexia. The increased R&D expenses reflect these advancements. Vistagen is optimistic about the transformative potential of its product candidates to address unmet needs in areas like social anxiety, major depressive disorder, and menopausal hot flashes, with 2025 poised as a pivotal year for data readouts and advancements.